|
US5804604A
(en)
|
1989-12-21 |
1998-09-08 |
Biogen, Inc. |
Tat-derived transport polypeptides and fusion proteins
|
|
ATE198277T1
(de)
|
1992-10-02 |
2001-01-15 |
Genetics Inst |
Zusammensetzung, welche den koagulationsfaktor viii beinhaltet; verfahren zu deren herstellung und die benutzung eines oberflächenaktiven stoffes als stabilisator
|
|
DE69434535T2
(de)
|
1993-12-28 |
2006-07-20 |
Allergan, Inc., Irvine |
Toxische Komponente der Botulinumtoxine zur Modulation cholinergisch kontrollierter Sekretionen
|
|
US5512547A
(en)
|
1994-10-13 |
1996-04-30 |
Wisconsin Alumni Research Foundation |
Pharmaceutical composition of botulinum neurotoxin and method of preparation
|
|
US5756468A
(en)
|
1994-10-13 |
1998-05-26 |
Wisconsin Alumni Research Foundation |
Pharmaceutical compositions of botulinum toxin or botulinum neurotoxin and methods of preparation
|
|
GB9508204D0
(en)
|
1995-04-21 |
1995-06-07 |
Speywood Lab Ltd |
A novel agent able to modify peripheral afferent function
|
|
US20030095927A1
(en)
|
1997-10-01 |
2003-05-22 |
Dugger Harry A. |
Buccal, polar and non-polar spray or capsule containing drugs for treating muscular and skeletal disorders
|
|
WO1999037326A1
(en)
|
1998-01-26 |
1999-07-29 |
University Of Massachusetts |
Biologically active hemagglutinin from type a clostridium botulinum and methods of use
|
|
TW574036B
(en)
|
1998-09-11 |
2004-02-01 |
Elan Pharm Inc |
Stable liquid compositions of botulinum toxin
|
|
US6358917B1
(en)
*
|
1999-08-24 |
2002-03-19 |
Jean D. A. Carruthers |
Cosmetic use of botulinum toxin for treatment of downturned mouth
|
|
US6544548B1
(en)
|
1999-09-13 |
2003-04-08 |
Keraplast Technologies, Ltd. |
Keratin-based powders and hydrogel for pharmaceutical applications
|
|
US6844324B1
(en)
|
1999-11-12 |
2005-01-18 |
Massachusetts Institute Of Technology |
Modular peptide mediated intracellular delivery system and uses therefore
|
|
IL149778A0
(en)
|
1999-11-22 |
2002-11-10 |
Universal Preservation Technologies Inc |
Preservation of sensitive biological material
|
|
ES2237551T3
(es)
|
2000-02-08 |
2005-08-01 |
Allergan, Inc. |
Composiciones farmaceuticas que contienen toxina botulinica.
|
|
US7780967B2
(en)
|
2000-02-08 |
2010-08-24 |
Allergan, Inc. |
Reduced toxicity Clostridial toxin pharmaceutical compositions
|
|
US20030118598A1
(en)
*
|
2000-02-08 |
2003-06-26 |
Allergan, Inc. |
Clostridial toxin pharmaceutical compositions
|
|
US6670322B2
(en)
|
2000-06-01 |
2003-12-30 |
Wisconsin Alumni Research Foundation |
Method of targeting pharmaceuticals to motor neurons
|
|
US20040033241A1
(en)
|
2000-06-02 |
2004-02-19 |
Allergan, Inc. |
Controlled release botulinum toxin system
|
|
US6306423B1
(en)
|
2000-06-02 |
2001-10-23 |
Allergan Sales, Inc. |
Neurotoxin implant
|
|
DK1301213T3
(en)
*
|
2000-07-21 |
2017-03-27 |
Revance Therapeutics Inc |
MULTI-COMPONENT SYSTEMS FOR BIOLOGICAL TRANSPORT
|
|
US20040220100A1
(en)
|
2000-07-21 |
2004-11-04 |
Essentia Biosystems, Inc. |
Multi-component biological transport systems
|
|
US7255865B2
(en)
*
|
2000-12-05 |
2007-08-14 |
Allergan, Inc. |
Methods of administering botulinum toxin
|
|
US6787517B1
(en)
*
|
2000-12-29 |
2004-09-07 |
Allergan, Inc. |
Agent and methods for treating pain
|
|
WO2003000193A2
(en)
|
2001-06-21 |
2003-01-03 |
Surromed, Inc. |
Covalent coupling of botulinum toxin with polyethylene glycol
|
|
WO2003068260A1
(fr)
*
|
2002-02-14 |
2003-08-21 |
Chugai Seiyaku Kabushiki Kaisha |
Produits pharmaceutiques en solution contenant des anticorps
|
|
US20030224020A1
(en)
|
2002-05-31 |
2003-12-04 |
Zabudkin Alexander F. |
Pharmaceutical preparation of botulinum neurotoxin, methods of synthesis and methods of clinical use
|
|
US20040009180A1
(en)
|
2002-07-11 |
2004-01-15 |
Allergan, Inc. |
Transdermal botulinum toxin compositions
|
|
US8119109B2
(en)
*
|
2002-10-25 |
2012-02-21 |
Foamix Ltd. |
Foamable compositions, kits and methods for hyperhidrosis
|
|
US9265725B2
(en)
*
|
2002-10-25 |
2016-02-23 |
Foamix Pharmaceuticals Ltd. |
Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
|
|
RU2206337C1
(ru)
|
2002-10-29 |
2003-06-20 |
Общество с ограниченной ответственностью "Токсины и сопутствующие продукты" |
Лекарственный препарат для лечения мышечных дистоний и способ его получения
|
|
US20040086532A1
(en)
|
2002-11-05 |
2004-05-06 |
Allergan, Inc., |
Botulinum toxin formulations for oral administration
|
|
DE10333317A1
(de)
*
|
2003-07-22 |
2005-02-17 |
Biotecon Therapeutics Gmbh |
Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA)
|
|
US20100266638A1
(en)
*
|
2004-02-26 |
2010-10-21 |
Allergan, Inc. |
Headache treatment method
|
|
BRPI0508440A
(pt)
*
|
2004-03-03 |
2007-07-24 |
Revance Therapeutics Inc |
composições e métodos para diagnóstico tópico e transporte terapêutico
|
|
US9211248B2
(en)
*
|
2004-03-03 |
2015-12-15 |
Revance Therapeutics, Inc. |
Compositions and methods for topical application and transdermal delivery of botulinum toxins
|
|
HUE025656T2
(en)
*
|
2004-03-03 |
2016-04-28 |
Revance Therapeutics Inc |
Topical application and transdermal delivery of botulinum toxins
|
|
GB2416122A
(en)
*
|
2004-07-12 |
2006-01-18 |
Ipsen Ltd |
Botulinum neurotoxin composition
|
|
EP1786459B1
(en)
*
|
2004-07-26 |
2014-02-12 |
Merz Pharma GmbH & Co. KGaA |
Therapeutic composition whit a botulinum neurotoxin
|
|
US20070196364A1
(en)
*
|
2004-07-27 |
2007-08-23 |
Human Genome Sciences, Inc. |
Pharmaceutical Formulation and Process
|
|
ES2526913T3
(es)
|
2004-08-04 |
2015-01-16 |
Ipsen Biopharm Limited |
Composición farmacéutica que contiene neurotoxina 2 botulínica
|
|
GB2419526A
(en)
|
2004-10-28 |
2006-05-03 |
Ipsen Ltd |
Pharmaceutical composition containing botulinum neurotoxin
|
|
WO2006013357A1
(en)
*
|
2004-08-04 |
2006-02-09 |
Ipsen Limited |
Pharmaceutical composition containing botulinum neurotoxin a2
|
|
US7727537B2
(en)
*
|
2005-02-14 |
2010-06-01 |
Dpm Therapeutics Corp. |
Stabilized compositions for topical administration and methods of making same
|
|
US9314431B2
(en)
*
|
2005-02-14 |
2016-04-19 |
Transdermal Corp |
Solubilized benzoyl small molecule
|
|
US7838011B2
(en)
*
|
2005-02-14 |
2010-11-23 |
Pankaj Modi |
Stabilized protein compositions for topical administration and methods of making same
|
|
KR20070110402A
(ko)
*
|
2005-03-03 |
2007-11-16 |
레반스 테라퓨틱스 |
보툴리눔 독소의 국소 적용 및 경피 전달을 위한 조성물 및방법
|
|
US8323666B2
(en)
*
|
2005-08-01 |
2012-12-04 |
Allergan, Inc. |
Botulinum toxin compositions
|
|
US8168206B1
(en)
*
|
2005-10-06 |
2012-05-01 |
Allergan, Inc. |
Animal protein-free pharmaceutical compositions
|
|
US8137677B2
(en)
*
|
2005-10-06 |
2012-03-20 |
Allergan, Inc. |
Non-protein stabilized clostridial toxin pharmaceutical compositions
|
|
WO2007059528A2
(en)
*
|
2005-11-17 |
2007-05-24 |
Revance Therapeutics, Inc. |
Compositions and methods of topical application and transdermal delivery of botulinum toxins with reduced non-toxin proteins
|
|
US9486408B2
(en)
*
|
2005-12-01 |
2016-11-08 |
University Of Massachusetts Lowell |
Botulinum nanoemulsions
|
|
US7899450B2
(en)
*
|
2006-03-01 |
2011-03-01 |
Telecommunication Systems, Inc. |
Cellular augmented radar/laser detection using local mobile network within cellular network
|
|
US20090123527A1
(en)
*
|
2006-07-24 |
2009-05-14 |
Akorn, Inc. |
Method of inducing topical anesthesia and transdermal patch
|
|
WO2008079464A2
(en)
*
|
2006-09-08 |
2008-07-03 |
Becton, Dickinson And Company |
Stable powder formulations of alum-adsorbed vaccines
|
|
CN101848702B
(zh)
*
|
2006-12-01 |
2013-07-17 |
安特里奥公司 |
两亲实体纳米粒子
|
|
AU2007234612B2
(en)
*
|
2006-12-14 |
2013-06-27 |
Johnson & Johnson Regenerative Therapeutics, Llc |
Protein stabilization formulations
|
|
FR2910327B1
(fr)
*
|
2006-12-22 |
2013-04-26 |
Scras |
Utilisation d'au moins une neurotoxine botulique pour traiter la douleur induite par les traitements therapeutiques du virus du sida.
|
|
WO2008082889A2
(en)
*
|
2006-12-29 |
2008-07-10 |
Revance Therapeutics, Inc. |
Compositions and methods of topical application and transdermal delivery of botulinum toxins stabilized with polypeptide fragments derived from hiv-tat
|
|
GB0700523D0
(en)
*
|
2007-01-11 |
2007-02-21 |
Insense Ltd |
The Stabilisation Of Proteins
|
|
AU2008256418A1
(en)
|
2007-06-01 |
2008-12-04 |
Merz Pharma Gmbh & Co. Kgaa |
Process for providing a temperature - stable muscle relaxant on the basis of the neurotoxic component of botulinum toxin in solid form
|
|
CA2690773C
(en)
*
|
2007-07-10 |
2013-09-17 |
Medy-Tox, Inc. |
Pharmaceutical liquid composition of botulinum toxin with improved stability
|
|
DK2178549T3
(en)
*
|
2007-07-26 |
2017-01-09 |
Revance Therapeutics Inc |
Antimicrobial peptide AND COMPOSITIONS THEREOF
|
|
WO2009056651A1
(en)
*
|
2007-11-02 |
2009-05-07 |
Cytos Biotechnology Ag |
Angiotensin-carrier formulation
|
|
US9107815B2
(en)
*
|
2008-02-22 |
2015-08-18 |
Allergan, Inc. |
Sustained release poloxamer containing pharmaceutical compositions
|
|
AU2009339292B2
(en)
*
|
2008-12-10 |
2016-01-21 |
Allergan, Inc. |
Clostridial toxin pharmaceutical compositions
|
|
LT2379104T
(lt)
*
|
2008-12-31 |
2018-04-10 |
Revance Therapeutics, Inc. |
Injekcinės botulino toksino vaisto formos
|
|
EP2248518B1
(en)
*
|
2009-04-17 |
2013-01-16 |
Merz Pharma GmbH & Co. KGaA |
Formulation for stabilizing proteins, peptides or mixtures thereof.
|
|
CN102869373B
(zh)
*
|
2009-06-25 |
2017-05-10 |
雷文斯治疗公司 |
不含白蛋白的肉毒杆菌毒素制剂
|
|
MX2012000372A
(es)
*
|
2009-07-06 |
2012-02-28 |
Variation Biotechnologies Inc |
Metodos para preparar vesiculas y formulaciones producidas a partir de las mismas.
|
|
WO2011028962A1
(en)
*
|
2009-09-04 |
2011-03-10 |
Xoma Technology Ltd. |
Antibody coformulations
|
|
US20120196349A1
(en)
*
|
2009-10-21 |
2012-08-02 |
Revance Therapeutics, Inc. |
Methods and Systems for Purifying Non-Complexed Botulinum Neurotoxin
|
|
AU2010312289B2
(en)
*
|
2009-10-30 |
2015-04-23 |
Duoject Medical Systems Inc. |
Inter vial transfer system
|
|
BR112012010058A2
(pt)
*
|
2009-10-30 |
2016-05-31 |
Duoject Inc |
aplicador tópico para um agente paralítico e método para aplicação do agente
|
|
JP5990176B2
(ja)
*
|
2010-10-12 |
2016-09-07 |
メルツ ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディト ゲゼルシャフト アウフ アクティーン |
タンパク質の安定化に好適な哺乳動物性賦形剤非含有製剤
|
|
ES3036435T3
(en)
*
|
2011-01-07 |
2025-09-18 |
Revance Therapeutics Inc |
Kits for topical application, removal, and inactivation of therapeutic or cosmetic botulinum toxin compositions
|
|
MX338436B
(es)
*
|
2011-03-31 |
2016-04-18 |
Medy Tox Inc |
Preparacion liofilizada de toxinas de botulismo.
|
|
WO2013130535A1
(en)
*
|
2012-02-27 |
2013-09-06 |
Newgen Biopharma Corporation |
Topical delivery of hormonal and non hormonal nano formulations, methods of making and using the same
|
|
WO2014066916A2
(en)
*
|
2012-10-28 |
2014-05-01 |
Revance Therapeutics, Inc. |
Compositions and methods for safe treatment of rhinitis
|
|
GB201407525D0
(en)
*
|
2014-04-29 |
2014-06-11 |
Syntaxin Ltd |
Manufacture of recombinant clostridium botulinum neurotoxins
|
|
MX380066B
(es)
|
2014-12-23 |
2025-03-11 |
Merz Pharma Gmbh & Co Kgaa |
Recipiente precargado con toxina botulinica.
|
|
CN109069608A
(zh)
*
|
2015-10-29 |
2018-12-21 |
雷文斯治疗公司 |
具有长的治疗或美容效应持续时间的可注射肉毒杆菌毒素制剂以及其使用方法
|
|
FI126979B
(en)
*
|
2016-02-29 |
2017-09-15 |
Faron Pharmaceuticals Oy |
Lyophilized pharmaceutical formulation and its use
|
|
CA3020400A1
(en)
*
|
2016-04-12 |
2017-10-19 |
Illustris Pharmaceuticals, Inc. |
Compositions for topical application of compounds
|
|
HRP20251606T1
(hr)
|
2016-05-27 |
2026-02-13 |
Ipsen Biopharm Limited |
Tekuća neurotoksinska formulacija stabilizirana s triptofanom ili tirozinom
|
|
EP3675900A4
(en)
*
|
2017-08-28 |
2021-05-05 |
Revance Therapeutics, Inc. |
Transmucosal botulinum toxin compositions, kits, and methods for treating bladder disorders
|
|
US20200390871A1
(en)
*
|
2017-11-03 |
2020-12-17 |
Revance Therapeutics, Inc. |
Botulinum toxin formulations and methods of use thereof in plantar fascitis with extended duration of effect
|
|
RU2020121540A
(ru)
*
|
2017-12-04 |
2022-01-10 |
Реванс Терапьютикс, Инк. |
Инъецируемые составы ботулинического токсина и способы их применения с высокими показателями ответа и длительной продолжительностью эффекта
|